CAGE Bio, Inc. is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement.
CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology. CGB-500 delivers medicine directly through the skin, with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics. Specifically, CGB-500 had an 8-week treatment success of 95% (Investigator’s Global Assessment or IGA core of “0” or “1” and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500.
